Recent developments in the health sector highlight diverse changes from drug pricing initiatives by Bristol Myers and Pfizer ...

Pfizer's stock decline due to COVID normalization presents opportunity for investors, with potential growth and dividend yield in 2024. Learn more on PFE stock here.

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Over the past 12 months, the XLV is up just 16.6%, while the S&P 500 is up 33.5%. The slumping stocks of big names like Pfizer and CVS have long been a drag on the sector.

While its shares have been lagging the market significantly, that could change in the next decade as financial results ...

Recent health news highlights various developments, including Trump's spending bill impacting insurance costs, a major acquisition in the bioscience sector, and GSK's efforts to expand RSV vaccine ...

The healthcare sector accounted for 17.6% of the US economy in 2023, up 17.4% from 2022. The two primary drivers of this rise are the expansion of private health insurance and Medicare.

Last month, news broke that Pfizer Inc. wanted to take over AstraZeneca. AstraZeneca has been fighting those advances. The standoff speaks to the changes taking place in the pharmaceutical sector.

Pfizer (PFE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Mohit Bansal from Wells Fargo maintained a Hold rating on the stock and ...

Pfizer Inc. (NYSE: PFE) today announced the completion of a $1.25 billion ten-year “sustainability” bond paying interest semi-annually of 2.625 percent and m ...

To help close this health equity gap, in May 2022 with African leaders from Rwanda, Ghana, Senegal and Malawi, Pfizer launched An Accord for a Healthier World (the Accord)—an initiative that is ...